Cardiovascular Assessment 5 Years After MIS-C

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMedical University of Warsaw

About this trial

Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormalities compared with healthy controls.

This cross-sectional study aims to evaluate cardiovascular health in individuals 5 years after MIS-C. Participants with a history of MIS-C will be compared with age- and sex-matched healthy controls using cardiovascular imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury.

Eligibility criteria

Qualifiers

For the MIS-C group: History of MIS-C diagnosed according to World Health Organization (WHO) criteria

For all participants: Written informed consent from a parent or legal guardian and, where applicable, assent/consent from participants aged 16 years or older /

Disqualifiers

Known heart disease, including congenital heart disease.

Significant chronic disease affecting growth, development, or daily functioning.

Elimination diet.

Competitive athletic training.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

90 Participants
are grouped into 2 trial groups

Sponsors and collaborators